Targeted approaches to triple-negative breast cancer: Current practice and future directions

Current Medicinal Chemistry

Volumn 20, Issue 5, 2013, Pages 605-612

  Brunello, A ^a   Borgato, L ^a   Basso, U ^a   Lumachi, F ^b   Zagonel, V ^a  

^a VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

Author keywords

Advanced breast cancer; Estrogen receptor; HER2; Progesterone receptor; Targeted therapy; Triple negative

Indexed keywords

ANTHRACYCLINE; BLEOMYCIN; BMN 673; CARBOPLATIN; CEP 9722; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ETOPOSIDE; FLUOROURACIL; GEFITINIB; GEMCITABINE; GPI 21016; INIPARIB; METHOTREXATE; MITOMYCIN; MONOCLONAL ANTIBODY; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; NIRAPARIB; NO 1001; OLAPARIB; PLATINUM DERIVATIVE; PROTEIN TYROSINE KINASE INHIBITOR; RUCAPARIB; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VELIPARIB;

ARTICLE; BASAL LIKE BREAST CANCER; BREAST CANCER; BREAST METASTASIS; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER RECURRENCE; CLINICAL FEATURE; COLORECTAL CANCER; HUMAN; IMMUNOHISTOCHEMISTRY; IONIZING RADIATION; LEUKEMIA; LIVER CANCER; NERVOUS SYSTEM TUMOR; OVARY CANCER; PROSTATE CANCER; TRIPLE NEGATIVE BREAST CANCER;

EID: 84877949661     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986713804999321     Document Type: Article

References (98)

1. National Comprehensive Cancer Network (NCCN) Guidelines, 2011, http://www.nccn.org/professionals/physician-gls/f-guidelines.asp
2. Slamon, D. J.; Clark, G. M.; Wong, S. G.; Levin, W. J.; Ullrich, A.; McGuire, W. L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science, 1987, 235, 177-182.
3. Ross, J. S.; Fletcher, J. A.; Bloom, K. J.; Linette, G. P.; Stec, J.; Symmans, W. F.; Pusztai, L.; Hortobagyi, G. N. Targeted therapy in breast cancer: the HER-2/neu gene and protein. Mol. Cell. Proteomics, 2004, 3, 379-398.
4. Dowsett, M.; Allred, C.; Knox, J.; Quinn, E.; Salter, J.; Wale, C.; Cuzick, J.; Houghton, J.; Williams, N.; Mallon, E.; Bishop, H.; Ellis, I.; Larsimont, D.; Sasano, H.; Carder, P.; Cussac, A. L.; Knox, F.; Speirs, V.; Forbes, J.; Buzdar, A. Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial. J. Clin. Oncol., 2008, 26, 1059-1065.
5. Hergueta-Redondo, M.; Palacios, J.; Cano, A.; Moreno-Bueno, G. "New" molecular taxonomy in breast cancer. Clin. Transl. Oncol., 2008, 10, 777-785.
6. Dent, R.; Trudeau, M.; Pritchard, K. I.; Hanna, W. M.; Kahn, H. K.; Sawka, C. A.; Lickley, L. A.; Rawlinson, E.; Sun, P.; Narod, S. A. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin. Cancer Res., 2007, 13, 4429-4434.
7. S Sørlie, T.; Perou, C.M.; Tibshirani, R.; Aas, T.; Geisler, S.; Johnsen, H.; Hastie, T.; Eisen, M.B.; van de Rijn, M.; Jeffrey, S.S.; Thorsen, T.; Quist, H.; Matese, J.C.; Brown, P.O.; Botstein, D.; Lønning, P.E.; Børresen-Dale, A.L. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci. U. S. A., 2001, 98, 10869-10874.
8. Liedtke, C.; Mazouni, C.; Hess, K. R.; Andre, F.; Tordai, A.; Mejia, J. A.; Symmans, W. F.; Gonzalez-Angulo, A. M.; Hennessy, B.; Green, M.; Cristofanilli, M.; Hortobagyi, G. N.; Pusztai, L. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J. Clin. Oncol., 2008, 26, 1275-1281.
9. Berry, D. A.; Cirrincione, C.; Henderson, I. C.; Citron, M. L.; Budman, D. R.; Goldstein, L. J.; Martino, S.; Perez, E. A.; Muss, H. B.; Norton, L.; Hudis, C.; Winer, E. P. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA, 2006, 295, 1658-1667.
10. Carey, L. A.; Perou, C. M.; Livasy, C. A.; Dressler, L. G.; Cowan, D.; Conway, K.; Karaca, G.; Troester, M. A.; Tse, C. K.; Edmiston, S.; Deming, S. L.; Geradts, J.; Cheang, M. C.; Nielsen, T. O.; Moorman, P. G.; Earp, H. S.; Millikan, R. C. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA, 2006, 295, 2492-2502.
11. Rouzier, R.; Perou, C. M.; Symmans, W. F.; Ibrahim, N.; Cristofanilli, M.; Anderson, K.; Hess, K. R.; Stec, J.; Ayers, M.; Wagner, P.; Morandi, P.; Fan, C.; Rabiul, I.; Ross, J. S.; Hortobagyi, G. N.; Pusztai, L. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin. Cancer Res., 2005, 11, 5678-5685.
12. Nielsen, T. O.; Hsu, F. D.; Jensen, K.; Cheang, M.; Karaca, G.; Hu, Z.; Hernandez-Boussard, T.; Livasy, C.; Cowan, D.; Dressler, L.; Akslen, L. A.; Ragaz, J.; Gown, A. M.; Gilks, C. B.; van de Rijn, M.; Perou, C. M. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin. Cancer Res., 2004, 10, 5367-5374.
13. Bertucci, F.; Finetti, P.; Cervera, N.; Esterni, B.; Hermitte, F.; Viens, P.; Birnbaum, D. How basal are triple-negative breast cancers ? Int. J. Cancer, 2008, 123, 236-240.
14. Cleator, S.; Heller, W.; Coombes, R. C. Triple-negative breast cancer: therapeutic options. Lancet Oncol., 2007, 8, 235-244.
15. Kreike, B.; van Kouwenhove, M.; Horlings, H.; Weigelt, B.; Peterse, H.; Bartelink, H.; van de Vijver, M. J. Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas. Breast Cancer Res., 2007, 9, R65.
16. Lakhani, S. R.; Van De Vijver, M. J.; Jacquemier, J.; Anderson, T. J.; Osin, P. P.; McGuffog, L.; Easton, D. F. The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J. Clin. Oncol., 2002, 20, 2310-2318.
17. Haffty, B. G.; Yang, Q.; Reiss, M.; Kearney, T.; Higgins, S. A.; Weidhaas, J.; Harris, L.; Hait, W.; Toppmeyer, D. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J. Clin. Oncol., 2006, 24, 5652-5657.
18. Atchley, D. P.; Albarracin, C. T.; Lopez, A.; Valero, V.; Amos, C. I.; Gonzalez-Angulo, A. M.; Hortobagyi, G. N.; Arun, B. K. Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. J. Clin. Oncol., 2008, 26, 4282-4288.
19. Fasano, J.; Muggia, F. Breast cancer arising in a BRCA-mutated background: therapeutic implications from an animal model and drug development. Ann. Oncol., 2009, 20, 609-614.
20. Foulkes, W. D.; Stefansson, I. M.; Chappuis, P. O.; Begin, L. R.; Goffin, J. R.; Wong, N.; Trudel, M.; Akslen, L. A. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J. Natl. Cancer Inst., 2003, 95, 1482-1485.
21. Reis-Filho, J. S.; Tutt, A. N. Triple negative tumours: a critical review. Histopathology, 2008, 52, 108-118.
22. Bauer, K. R.; Brown, M.; Cress, R. D.; Parise, C. A.; Caggiano, V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triplenegative phenotype: a population-based study from the California cancer Registry. Cancer, 2007, 109, 1721-1728.
23. Morris, G. J.; Naidu, S.; Topham, A. K.; Guiles, F.; Xu, Y.; McCue, P.; Schwartz, G. F.; Park, P. K.; Rosenberg, A. L.; Brill, K.; Mitchell, E. P. Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: a single-institution compilation compared with the National Cancer Institute. Surveillance, Epidemiology, and End Results database. Cancer, 2007, 110, 876-884.
24. Carey, L. A.; Dees, E. C.; Sawyer, L.; Gatti, L.; Moore, D. T.; Collichio, F.; Ollila, D. W.; Sartor, C. I.; Graham, M. L.; Perou, C. M. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin. Cancer Res., 2007, 13, 2329-2334.
25. Millikan, R. C.; Newman, B.; Tse, C. K.; Moorman, P. G.; Conway, K.; Dressler, L. G.; Smith, L. V.; Labbok, M. H.; Geradts, J.; Bensen, J. T.; Jackson, S.; Nyante, S.; Livasy, C.; Carey, L.; Earp, H. S.; Perou, C. M. Epidemiology of basal-like breast cancer. Breast Cancer Res. Treat., 2008, 109, 123-139.
26. Livasy, C. A.; Karaca, G.; Nanda, R.; Tretiakova, M. S.; Olopade, O. I.; Moore, D. T.; Perou, C. M. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod. Pathol., 2006, 19, 264-271.
27. Khalifeh, I. M.; Albarracin, C.; Diaz, L. K.; Symmans, F. W.; Edgerton, M. E.; Hwang, R. F.; Sneige, N. Clinical, histopathologic, and immunohistochemical features of microglandular adenosis and transition into in situ and invasive carcinoma. Am. J. Surg. Pathol., 2008, 32, 544-552.
28. Bocker, W.; Bier, B.; Freytag, G.; Brommelkamp, B.; Jarasch, E. D.; Edel, G.; Dockhorn-Dworniczak, B.; Schmid, K. W. An immunohistochemical study of the breast using antibodies to basal and luminal keratins, alphasmooth muscle actin, vimentin, collagen IV and laminin. Part II: Epitheliosis and ductal carcinoma in situ. Virchows Arch. A. Pathol. Anat. Histopathol., 1992, 421, 323-330.
29. Gottlieb, C.; Raju, U.; Greenwald, K. A. Myoepithelial cells in the differential diagnosis of complex benign and malignant breast lesions: an immunohistochemical study. Mod. Pathol., 1990, 3, 135-140.
30. Lazard, D.; Sastre, X.; Frid, M. G.; Glukhova, M. A.; Thiery, J. P.; Koteliansky, V. E. Expression of smooth muscle-specific proteins in myoepithelium and stromal myofibroblasts of normal and malignant human breast tissue. Proc. Natl. Acad. Sci. U. S. A., 1993, 90, 999-1003.
31. Nakano, S.; Iyama, K.; Ogawa, M.; Yoshioka, H.; Sado, Y.; Oohashi, T.; Ninomiya, Y. Differential tissular expression and localization of type IV collagen alpha1(IV), alpha2(IV), alpha5(IV), and alpha6(IV) chains and their mRNA in normal breast and in benign and malignant breast tumors. Lab. Invest., 1999, 79, 281-292.
32. Collett, K.; Stefansson, I. M.; Eide, J.; Braaten, A.; Wang, H.; Eide, G. E.; Thoresen, S. O.; Foulkes, W. D.; Akslen, L. A. A basal epithelial phenotype is more frequent in interval breast cancers compared with screen detected tumors. Cancer Epidemiol. Biomarkers Prev., 2005, 14, 1108-1112.
33. Rakha, E. A.; Elsheikh, S. E.; Aleskandarany, M. A.; Habashi, H. O.; Green, A. R.; Powe, D. G.; El-Sayed, M. E.; Benhasouna, A.; Brunet, J. S.; Akslen, L. A.; Evans, A. J.; Blamey, R.; Reis-Filho, J. S.; Foulkes, W. D.; Ellis, I. O. Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes. Clin. Cancer Res., 2009, 15, 2302-2310.
34. Bhattacharyya, A.; Ear, U. S.; Koller, B. H.; Weichselbaum, R. R.; Bishop, D. K. The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin. J. Biol. Chem., 2000, 275, 23899-23903.
35. Moynahan, M. E.; Cui, T. Y.; Jasin, M. Homology-directed DNA repair, mitomycin-c resistance, and chromosome stability is restored with correction of a Brca1 mutation. Cancer Res. 2001, 61, 4842-4850.
36. Dawson, S. J.; Provenzano, E.; Caldas, C. Triple negative breast cancers: clinical and prognostic implications. Eur. J. Cancer, 2009, 45 Suppl 1, 27-40.
37. Ozkan, M.; Berk, V.; Kaplan, M. A.; Benekli, M.; Coskun, U.; Bilici, A.; Gumus, M.; Alkis, N.; Dane, F.; Ozdemir, N. Y.; Colak, D.; Dikilitas, M. Gemcitabine and cisplatin combination chemotherapy in triple negative metastatic breast cancer previously treated with a taxane/anthracycline chemotherapy; multicenter experience. Neoplasma, 2012, 59, 38-42.
38. Levine, M. N.; Bramwell, V. H.; Pritchard, K. I.; Norris, B. D.; Shepherd, L. E.; Abu-Zahra, H.; Findlay, B.; Warr, D.; Bowman, D.; Myles, J.; Arnold, A.; Vandenberg, T.; MacKenzie, R.; Robert, J.; Ottaway, J.; Burnell, M.; Williams, C. K.; Tu, D. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol., 1998, 16, 2651-2658.
39. Cheang, M. C.; Chia, S. K.; Voduc, D.; Gao, D.; Leung, S.; Snider, J.; Watson, M.; Davies, S.; Bernard, P. S.; Parker, J. S.; Perou, C. M.; Ellis, M. J.; Nielsen, T. O. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J. Natl. Cancer Inst., 2009, 101, 736-750.
40. Gennari, A.; Sormani, M. P.; Pronzato, P.; Puntoni, M.; Colozza, M.; Pfeffer, U.; Bruzzi, P. HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials. J. Natl. Cancer Inst., 2008, 100, 14-20.
41. Tan, D. S.; Marchio, C.; Jones, R. L.; Savage, K.; Smith, I. E.; Dowsett, M.; Reis-Filho, J. S. Triple-negative breast cancer: Molecular profiling and prognostic impact in adjuvant anthracycline-treated patients. Breast Cancer Res. Treat., 2008, 111, 27-44.
42. Lehmann-Che, J.; Andre, F.; Desmedt, C.; Mazouni, C.; Giacchetti, S.; Turpin, E.; Espie, M.; Plassa, L. F.; Marty, M.; Bertheau, P.; Sotiriou, C.; Piccart, M.; Symmans, W. F.; Pusztai, L.; de The, H. Cyclophosphamide dose intensification may circumvent anthracycline resistance of p53 mutant breast cancers. Oncologist, 2010, 15, 246-252.
43. O. Malley, F. P.; Chia, S.; Tu, D.; Shepherd, L. E.; Levine, M. N.; Bramwell, V. H.; Andrulis, I. L.; Pritchard, K. I. Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy. J. Natl. Cancer Inst., 2009, 101, 644-650.
44. Turner, N.; Tutt, A.; Ashworth, A. Targeting the DNA repair defect of BRCA tumours. Curr. Opin. Pharmacol. 2005, 5, 388-393.
45. Farmer, H.; McCabe, N.; Lord, C. J.; Tutt, A. N.; Johnson, D. A.; Richardson, T. B.; Santarosa, M.; Dillon, K. J.; Hickson, I.; Knights, C.; Martin, N. M.; Jackson, S. P.; Smith, G. C.; Ashworth, A. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature, 2005, 434, 917-921.
46. Tutt, A. N.; Lord, C. J.; McCabe, N.; Farmer, H.; Turner, N.; Martin, N. M.; Jackson, S. P.; Smith, G. C.; Ashworth, A. Exploiting the DNA repair defect in BRCA mutant cells in the design of new therapeutic strategies for cancer. Cold Spring Harb. Symp. Quant. Biol. 2005, 70, 139-148.
47. Quinn, J. E.; Kennedy, R. D.; Mullan, P. B.; Gilmore, P. M.; Carty, M.; Johnston, P. G.; Harkin, D. P. BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. Cancer Res., 2003, 63, 6221-6228.
48. Mason, K. A.; Valdecanas, D.; Hunter, N. R.; Milas, L. INO-1001, a novel inhibitor of poly(ADP-ribose) polymerase, enhances tumor response to doxorubicin. Invest. New Drugs, 2008, 26, 1-5.
49. Racz, I.; Tory, K.; Gallyas, F.,Jr.; Berente, Z.; Osz, E.; Jaszlits, L.; Bernath, S.; Sumegi, B.; Rabloczky, G.; Literati-Nagy, P. BGP-15 -A novel poly(ADP-ribose) polymerase inhibitor -protects against nephrotoxicity of cisplatin without compromising its antitumor activity. Biochem. Pharmacol., 2002, 63, 1099-1111.
50. Bryant, H. E.; Schultz, N.; Thomas, H. D.; Parker, K. M.; Flower, D.; Lopez, E.; Kyle, S.; Meuth, M.; Curtin, N. J.; Helleday, T. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature, 2005, 434, 913-917.
51. Schreiber, V.; Dantzer, F.; Ame, J. C.; de Murcia, G. Poly(ADP-ribose): Novel functions for an old molecule. Nat. Rev. Mol. Cell Biol., 2006, 7, 517-528.
52. Boehler, C.; Gauthier, L. R.; Mortusewicz, O.; Biard, D. S.; Saliou, J. M.; Bresson, A.; Sanglier-Cianferani, S.; Smith, S.; Schreiber, V.; Boussin, F.; Dantzer, F. Poly(ADP-ribose) polymerase 3 (PARP3), a newcomer in cellu lar response to DNA damage and mitotic progression. Proc. Natl. Acad. Sci. U. S. A., 2011, 108, 2783-2788.
53. de Murcia, G.; Schreiber, V.; Molinete, M.; Saulier, B.; Poch, O.; Masson, M.; Niedergang, C.; Menissier de Murcia, J. Structure and function of poly(ADP-ribose) polymerase. Mol. Cell. Biochem., 1994, 138, 15-24.
54. Ahel, D.; Horejsi, Z.; Wiechens, N.; Polo, S. E.; Garcia-Wilson, E.; Ahel, I.; Flynn, H.; Skehel, M.; West, S. C.; Jackson, S. P.; Owen-Hughes, T.; Boulton, S. J. Poly(ADP-ribose)-dependent regulation of DNA repair by the chromatin remodeling enzyme ALC1. Science, 2009, 325, 1240-1243.
55. Timinszky, G.; Till, S.; Hassa, P. O.; Hothorn, M.; Kustatscher, G.; Nijmeijer, B.; Colombelli, J.; Altmeyer, M.; Stelzer, E. H.; Scheffzek, K.; Hottiger, M. O.; Ladurner, A. G. A macrodomain-containing histone rearranges chromatin upon sensing PARP1 activation. Nat. Struct. Mol. Biol., 2009, 16, 923-929.
56. Alli, E.; Sharma, V. B.; Sunderesakumar, P.; Ford, J. M. Defective repair of oxidative DNA damage in triple-negative breast cancer confers sensitivity to inhibition of poly(ADP-ribose) polymerase. Cancer Res., 2009, 69, 3589-3596.
57. Mendeleyev, J.; Kirsten, E.; Hakam, A.; Buki, K. G.; Kun, E. Potential chemotherapeutic activity of 4-iodo-3-nitrobenzamide. Metabolic reduction to the 3-nitroso derivative and induction of cell death in tumor cells in culture. Biochem. Pharmacol., 1995, 50, 705-714.
58. O. Shaughnessy, J.; Osborne, C.; Pippen, J. E.; Yoffe, M.; Patt, D.; Rocha, C.; Koo, I. C.; Sherman, B. M.; Bradley, C. Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N. Engl. J. Med., 2011, 364, 205-214.
59. Rottenberg, S.; Jaspers, J. E.; Kersbergen, A.; van der Burg, E.; Nygren, A. O.; Zander, S. A.; Derksen, P. W.; de Bruin, M.; Zevenhoven, J.; Lau, A.; Boulter, R.; Cranston, A.; O. Connor, M. J.; Martin, N. M.; Borst, P.; Jonkers, J. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc. Natl. Acad. Sci. U. S. A., 2008, 105, 17079-17084.
60. Fong, P. C.; Boss, D. S.; Yap, T. A.; Tutt, A.; Wu, P.; Mergui-Roelvink, M.; Mortimer, P.; Swaisland, H.; Lau, A.; O. Connor, M. J.; Ashworth, A.; Carmichael, J.; Kaye, S. B.; Schellens, J. H.; de Bono, J. S. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N. Engl. J. Med., 2009, 361, 123-134.
61. Tutt, A.; Robson, M.; Garber, J. E.; Domchek, S. M.; Audeh, M. W.; Weitzel, J. N.; Friedlander, M.; Arun, B.; Loman, N.; Schmutzler, R. K.; Wardley, A.; Mitchell, G.; Earl, H.; Wickens, M.; Carmichael, J. Oral poly (ADPribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet, 2010, 376, 235-244.
62. Thomas, H. D.; Calabrese, C. R.; Batey, M. A.; Canan, S.; Hostomsky, Z.; Kyle, S.; Maegley, K. A.; Newell, D. R.; Skalitzky, D.; Wang, L. Z.; Webber, S. E.; Curtin, N. J. Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial. Mol. Cancer. Ther., 2007, 6, 945-956.
63. Donawho, C. K.; Luo, Y.; Luo, Y.; Penning, T. D.; Bauch, J. L.; Bouska, J. J.; Bontcheva-Diaz, V. D.; Cox, B. F.; DeWeese, T. L.; Dillehay, L. E.; Ferguson, D. C.; Ghoreishi-Haack, N. S.; Grimm, D. R.; Guan, R.; Han, E. K.; Holley-Shanks, R. R.; Hristov, B.; Idler, K. B.; Jarvis, K.; Johnson, E. F.; Kleinberg, L. R.; Klinghofer, V.; Lasko, L. M.; Liu, X.; Marsh, K. C.; McGonigal, T. P.; Meulbroek, J. A.; Olson, A. M.; Palma, J. P.; Rodriguez, L. E.; Shi, Y.; Stavropoulos, J. A.; Tsurutani, A. C.; Zhu, G. D.; Rosenberg, S. H.; Giranda, V. L.; Frost, D. J. ABT-888, an orally active poly(ADPribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin. Cancer Res., 2007, 13, 2728-2737.
64. Javle, M.; Curtin, N. J. The potential for poly (ADP-ribose) polymerase inhibitors in cancer therapy. Ther. Adv. Med. Oncol., 2011, 3, 257-267.
65. Baselga, J.; Stemmer, S.; Pego, A.; Chan, A.; Goeminne, J.; Graas, P.; Kennedy, J.; Ciruelos Gil, V.; Zubel, A.; Groos, J.; Kia, V.; Schneeweiss, A. Cetuximab + Cisplatin in Estrogen Receptor-Negative, Progesterone Receptor-Negative, HER2-Negative (Triple-Negative) Metastatic Breast Cancer: Results of the Randomized Phase II BALI-1 Trial. Cancer Res., 2010, 70 Suppl 24, abstract PD01-01.
66. Pore, N.; Jiang, Z.; Shu, H. K.; Bernhard, E.; Kao, G. D.; Maity, A. Akt1 activation can augment hypoxia-inducible factor-1alpha expression by increasing protein translation through a mammalian target of rapamycinindependent pathway. Mol. Cancer. Res., 2006, 4, 471-479.
67. Jiang, Z. Y.; Chawla, A.; Bose, A.; Way, M.; Czech, M. P. A phosphatidylinositol 3-kinase-independent insulin signaling pathway to NWASP/Arp2/3/F-Actin required for GLUT4 glucose transporter recycling. J. Biol. Chem., 2002, 277, 509-515.
68. El Guerrab, A.; Zegrour, R.; Nemlin, C. C.; Vigier, F.; Cayre, A.; Penault-Llorca, F.; Rossignol, F.; Bignon, Y. J. Differential impact of EGFR-targeted therapies on hypoxia responses: implications for treatment sensitivity in triple-negative metastatic breast cancer. PLoS One, 2011, 6, e25080.
69. O. Shaughnessy, J.; Weckstein, D. J.; Vukelja, S. J. Preliminary results of a randomized phase II study of weekly irinotecan/carboplatin with or without cetuximab in patients with metastatic breast cancer. Breast Cancer Res. Treat., 2007, 106 suppl 1, S32.
70. Carey, L. A.; Rugo, H. S.; Marcom, P. K.; Mayer, E. L.; Esteva, F. J.; Ma, C. X.; Liu, M. C.; Storniolo, A. M.; Rimawi, M. F.; Forero-Torres, A.; Wolff, A. C.; Hobday, T. J.; Ivanova, A.; Chiu, W. K.; Ferraro, M.; Burrows, E.; Bernard, P. S.; Hoadley, K.,A.; Perou, C. M.; Winer, E. P. TBCRC 001: EGFR inhibition with cetuximab added to carboplatin in metastatic triplenegative (basal-like) breast cancer. J. Clin. Oncol., 2008, 26 suppl 15, abstract 1009.
71. Broekman, F.; Giovannetti, E.; Peters, G. J. Tyrosine kinase inhibitors: Multi-targeted or single-targeted? World J. Clin. Oncol. 2011, 2, 80-93.
72. Hanahan, D.; Weinberg, R. A. Hallmarks of cancer: the next generation. Cell, 2011, 144, 646-674.
73. Burstein, H. J.; Elias, A. D.; Rugo, H. S.; Cobleigh, M. A.; Wolff, A. C.; Eisenberg, P. D.; Lehman, M.; Adams, B. J.; Bello, C. L.; DePrimo, S. E.; Baum, C. M.; Miller, K. D. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J. Clin. Oncol., 2008, 26, 1810-1816.
74. Finn, R. S.; Dering, J.; Ginther, C.; Wilson, C. A.; Glaspy, P.; Tchekmedyian, N.; Slamon, D. J. Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triplenegative" breast cancer cell lines growing in vitro. Breast Cancer Res. Treat., 2007, 105, 319-326.
75. Aleshin, A.; Finn, R. S. SRC: a century of science brought to the clinic. Neoplasia, 2010, 12, 599-607.
76. Litwiniuk, M. M.; Roznowski, K.; Filas, V.; Godlewski, D. D.; Stawicka, M.; Kaleta, R.; Breborowicz, J. Expression of estrogen receptor beta in the breast carcinoma of BRCA1 mutation carriers. BMC Cancer, 2008, 8, 100.
77. Lin, C. Y.; Strom, A.; Li Kong, S.; Kietz, S.; Thomsen, J. S.; Tee, J. B.; Vega, V. B.; Miller, L. D.; Smeds, J.; Bergh, J.; Gustafsson, J. A.; Liu, E. T. Inhibitory effects of estrogen receptor beta on specific hormone-responsive gene expression and association with disease outcome in primary breast cancer. Breast Cancer Res., 2007, 9, R25.
78. Hartman, J.; Lindberg, K.; Morani, A.; Inzunza, J.; Strom, A.; Gustafsson, J. A. Estrogen receptor beta inhibits angiogenesis and growth of T47D breast cancer xenografts. Cancer Res., 2006, 66, 11207-11213.
79. Chang, E. C.; Frasor, J.; Komm, B.; Katzenellenbogen, B. S. Impact of estrogen receptor beta on gene networks regulated by estrogen receptor alpha in breast cancer cells. Endocrinology, 2006, 147, 4831-4842.
80. Paruthiyil, S.; Parmar, H.; Kerekatte, V.; Cunha, G. R.; Firestone, G. L.; Leitman, D. C. Estrogen receptor beta inhibits human breast cancer cell proliferation and tumor formation by causing a G2 cell cycle arrest. Cancer Res., 2004, 64, 423-428.
81. Williams, C.; Edvardsson, K.; Lewandowski, S. A.; Strom, A.; Gustafsson, J. A. A genome-wide study of the repressive effects of estrogen receptor beta on estrogen receptor alpha signaling in breast cancer cells. Oncogene, 2008, 27, 1019-1032.
82. Murphy, L. C.; Watson, P. H. Is oestrogen receptor-beta a predictor of endocrine therapy responsiveness in human breast cancer ? Endocr. Relat. Cancer, 2006, 13, 327-334.
83. Skliris, G. P.; Lewis, A.; Emberley, E.; Peng, B.; Weebadda, W. K.; Kemp, A.; Davie, J. R.; Shiu, R. P.; Watson, P. H.; Murphy, L. C. Estrogen receptor-beta regulates psoriasin (S100A7) in human breast cancer. Breast Cancer Res. Treat., 2007, 104, 75-85.
84. Skliris, G. P.; Leygue, E.; Curtis-Snell, L.; Watson, P. H.; Murphy, L. C. Expression of oestrogen receptor-beta in oestrogen receptor-Alpha negative human breast tumours. Br. J. Cancer, 2006, 95, 616-626.
85. Skliris, G. P.; Leygue, E.; Watson, P. H.; Murphy, L. C. Estrogen receptor alpha negative breast cancer patients: estrogen receptor beta as a therapeutic target. J. Steroid Biochem. Mol. Biol., 2008, 109, 1-10.
86. Gruvberger-Saal, S. K.; Bendahl, P. O.; Saal, L. H.; Laakso, M.; Hegardt, C.; Eden, P.; Peterson, C.; Malmstrom, P.; Isola, J.; Borg, A.; Ferno, M. Estrogen receptor beta expression is associated with tamoxifen response in ERalpha-negative breast carcinoma. Clin. Cancer Res., 2007, 13, 1987-1994.
87. Mandusic, V.; Nikolic-Vukosavljevic, D.; Tanic, N.; Kanjer, K.; Neskovic-Konstantinovic, Z.; Celeketic, D.; Dimitrijevic, B. Expression of estrogen receptor beta wt isoform (ERbeta1) and ERbetaDelta5 splice variant mRNAs in sporadic breast cancer. J. Cancer Res. Clin. Oncol., 2007, 133, 571-579.
88. Novelli, F.; Milella, M.; Melucci, E.; Di Benedetto, A.; Sperduti, I.; Perrone-Donnorso, R.; Perracchio, L.; Venturo, I.; Nistico, C.; Fabi, A.; Buglioni, S.; Natali, P. G.; Mottolese, M. A divergent role for estrogen receptor-beta in node-positive and node-negative breast cancer classified according to molecular subtypes: an observational prospective study. Breast Cancer Res., 2008, 10, R74.
89. Poola, I.; Abraham, J.; Baldwin, K.; Saunders, A.; Bhatnagar, R. Estrogen receptors beta4 and beta5 are full length functionally distinct ERbeta isoforms: cloning from human ovary and functional characterization. Endocrine, 2005, 27, 227-238.
90. McGhan, L. J.; McCullough, A. E.; Protheroe, C. A.; Dueck, A. C.; Lee, J. J.; Nunez, R.; Castle, E. P.; Gray, R. J.; Wasif, N.; Goetz, M. P.; Hawse, J. R.; Henry, T. J.; Barrett, M. T.; Heather, C. E.; Pockaj, B. A. Androgen Receptor-Positive Triple Negative Breast Cancer: A Unique Breast Cancer Subtype. Ann. Surg. Oncol., 2012, 19 suppl 12, abstract 22.
91. Agoff, S. N.; Swanson, P. E.; Linden, H.; Hawes, S. E.; Lawton, T. J. Androgen receptor expression in estrogen receptor-negative breast cancer. Immunohistochemical, clinical, and prognostic associations. Am. J. Clin. Pathol., 2003, 120, 725-731.
92. Moinfar, F.; Okcu, M.; Tsybrovskyy, O.; Regitnig, P.; Lax, S. F.; Weybora, W.; Ratschek, M.; Tavassoli, F. A.; Denk, H. Androgen receptors frequently are expressed in breast carcinomas: potential relevance to new therapeutic strategies. Cancer, 2003, 98, 703-711.
93. Loibl, S.; Muller, B. M.; von Minckwitz, G.; Schwabe, M.; Roller, M.; Darb-Esfahani, S.; Ataseven, B.; du Bois, A.; Fissler-Eckhoff, A.; Gerber, B.; Kulmer, U.; Alles, J. U.; Mehta, K.; Denkert, C. Androgen receptor expression in primary breast cancer and its predictive and prognostic value in patients treated with neoadjuvant chemotherapy. Breast Cancer Res. Treat., 2011, 130, 477-487.
94. Yu, Q.; Niu, Y.; Liu, N.; Zhang, J. Z.; Liu, T. J.; Zhang, R. J.; Wang, S. L.; Ding, X. M.; Xiao, X. Q. Expression of androgen receptor in breast cancer and its significance as a prognostic factor. Ann. Oncol., 2011, 22, 1288-1294.
95. Gucalp, A.; Traina, T. A. Triple-negative breast cancer: role of the androgen receptor. Cancer J., 2010, 16, 62-65.
96. Melhem-Bertrandt, A.; Chavez-Macgregor, M.; Lei, X.; Brown, E. N.; Lee, R. T.; Meric-Bernstam, F.; Sood, A. K.; Conzen, S. D.; Hortobagyi, G. N.; Gonzalez-Angulo, A. M. Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer. J. Clin. Oncol., 2011, 29, 2645-2652.
97. Piechocki, M. P.; Wu, G. S.; Jones, R. F.; Jacob, J. B.; Gibson, H.; Ethier, S. P.; Abrams, J.; Yagita, H.; Venuprasad, K.; Wei, W. Z. Induction of proapoptotic antibodies to triple-negative breast cancer by vaccination with TRAIL death receptor DR5 DNA. Int. J. Cancer, 2012, 131, 2562-2572.
98. Girgert, R.; Emons, G.; Grundker, C. Inactivation of GPR30 reduces growth of triple-negative breast cancer cells: possible application in targeted therapy. Breast Cancer Res. Treat., 2012, 134, 199-205.